Register entry
- Registered sites
- 0
- Active NDC listings
- 23
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
2323 active NDC listings: 21 drug for further processing, 2 bulk ingredient. By marketing category: DRUG FOR FURTHER PROCESSING 21, BULK INGREDIENT 2.
| Dosage form | NDCs |
|---|---|
| tablet | 15 |
| tablet, film coated | 5 |
| powder | 3 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| abbvie ireland nl b.v. | 23 |
Catalogue
Marketed products
23| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Elagolix | tablet, film coated | 68513-0038DRUG FOR FURTHER PROCESSING |
| - | Elagolix | tablet, film coated | 68513-0039DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-3727DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-4341DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-4552DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-5182DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-6594DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-6624DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-7068DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-7069DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-7070DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-7148DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-7149DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | powder | 68513-7155DRUG FOR FURTHER PROCESSING |
| - | Levothyroxine Sodium | tablet | 68513-9296DRUG FOR FURTHER PROCESSING |
| - | Paricalcitol | powder | 68513-1054BULK INGREDIENT |
| - | Upadacitinib | tablet | 68513-2306DRUG FOR FURTHER PROCESSING |
| - | Upadacitinib | tablet | 68513-2310DRUG FOR FURTHER PROCESSING |
| - | Upadacitinib | powder | 68513-2320BULK INGREDIENT |
| - | Venetoclax | tablet, film coated | 68513-0561DRUG FOR FURTHER PROCESSING |
| - | Venetoclax | tablet, film coated | 68513-0566DRUG FOR FURTHER PROCESSING |
| - | Venetoclax | tablet, film coated | 68513-0576DRUG FOR FURTHER PROCESSING |
| - | upadacitinib | tablet | 68513-1043DRUG FOR FURTHER PROCESSING |
Compare
Other companies listing levothyroxine sodium
- Cardinal Health 418, Inc.34 sites · 833 NDC
- Lupin Limited14 sites · 506 NDC
- AbbVie Inc.13 sites · 131 NDC
- MSN Laboratories Private Limited,8 sites · 275 NDC
- Aurobindo Pharma Limited6 sites · 1,453 NDC
- Fresenius Kabi USA, LLC6 sites · 561 NDC
- Spectrum Pharmaceuticals, Inc.6 sites · 240 NDC
- Pharma Packaging Solutions, LLC dba Tjoapack, LLC5 sites · 667 NDC
- Sandoz Industrial Products S.A5 sites · 441 NDC
- International Medication Systems, Ltd.3 sites · 2,801 NDC
Enquiry
Common questions
- Is AbbVie Ireland NL B.V. FDA approved?
- AbbVie Ireland NL B.V. holds no registered establishment of its own; 23 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does AbbVie Ireland NL B.V. make?
- 23 products are listed under AbbVie Ireland NL B.V. in the openFDA NDC Directory, most often as tablet; tablet, film coated; powder. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.